Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

This study is a prospective, open-label, randomized, multicenter, two-cohort phase II clinical trial. Starting from December 1, 2024, it plans to enroll 120 patients with advanced first-line HR-positive, HER2-negative breast cancer. A centralized randomization system (IWRS) will be used for randomization, and stratification will be performed based on the following factors during randomization: 1) Visceral metastasis (yes vs no); 2) Disease-free interval (previously untreated vs 12 \< DFI ≤ 24 vs DFI \> 24). Cohort A: Dalpiciclib 125mg + Letrozole 2.5mg Cohort B: Dalpiciclib 150mg + Letrozole

Trial Details

NCT ID
NCT07285382
Phase
PHASE2
Sponsor
wanghaibo
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Dalpiciclib 125mg
  • Dalpiciclib 150mg
  • Letrozole 2.5mg
Locations (sample)
  • Dalian, Liaoning, China|38.91222,121.60222
  • Qingdao, Shandong, China|36.06488,120.38042

Key Eligibility Criteria

  • Female patients aged ≥18 years and ≤75 years, who are postmenopausal or premenopausal/perimenopausal, and meet one of the following conditions:
  • Have undergone bilateral oophorectomy in the past, or be aged ≥60 years; or
  • Aged \<60 years, in a natural postmenopausal state (defined as spontaneous cessation of regular menstruation for at least 12 consecutive months wit…
  • Premenopausal or perimenopausal female patients can also be enrolled, but must be willing to receive LHRH agonist treatment during the study period

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →